

# Annexe 1

## MATÉRIEL SUPPLÉMENTAIRE DE L'ARTICLE

647 Étude de la résistance de *Plasmodium falciparum* aux antipaludiques au sein du réseau international des Instituts Pasteur (RIIP-Palu)

Didier Ménard, Frédéric Arieu, Odile Mercereau-Puijalon

**Med Sci (Paris) 2013 ; 29 (6-7) : 647–655**

DOI : [10.1051/medsci/2013296020](https://doi.org/10.1051/medsci/2013296020)

## RÉFÉRENCES

1. Adou-Bryn KD, Krelo K, Akoussi CF, *et al.* Efficacité thérapeutique de la chloroquine dans le traitement du paludisme simple dû à *Plasmodium falciparum* des consultants hospitaliers dans le centre de la Côte d'Ivoire (1997-2000). *Bull Soc Pathol Exot* 2002 ; 95 : 262-4.
2. Ako BA, Offianan AT, Johansson M, *et al.* Molecular analysis of markers associated with chloroquine and sulfadoxine/pyrimethamine resistance in *Plasmodium falciparum* malaria parasites from southeastern Côte-d'Ivoire by the time of artemisinin-based combination therapy adoption in 2005. *Infect Drug Resist* 2012 ; 5 : 113-20.
3. Alker AP, Lim P, Sem R, *et al.* Pfm<sup>dr1</sup> and *in vivo* resistance to artesunate-mefloquine in *falciparum* malaria on the Cambodian-Thai border. *Am J Trop Med Hyg* 2007 ; 76 : 641-7.
4. Andriantsoanirina V, Bouchier C, Tichit M, *et al.* Origins of the recent emergence of *Plasmodium falciparum* pyrimethamine resistance alleles in Madagascar. *Antimicrob Agents Chemother* 2010 ; 54 : 2323-9.
5. Andriantsoanirina V, Durand R, Pradines B, *et al.* *In vitro* susceptibility to pyrimethamine of DHFR I164L single mutant *Plasmodium falciparum*. *Malar J* 2011 ; 10 : 283.
6. Andriantsoanirina V, Khim N, Ratsimbao A, *et al.* *Plasmodium falciparum* Na<sup>+</sup>/H<sup>+</sup> exchanger (pfnhe-1) genetic polymorphism in Indian Ocean malaria-endemic areas. *Am J Trop Med Hyg* 2012 ; 88 : 37-42.
7. Andriantsoanirina V, Menard D, Rabearimanana S, *et al.* Association of microsatellite variations of *Plasmodium falciparum* Na<sup>+</sup>/H<sup>+</sup> exchanger (Pfnhe-1) gene with reduced *in vitro* susceptibility to quinine: lack of confirmation in clinical isolates from Africa. *Am J Trop Med Hyg* 2010 ; 82 : 782-7.

8. Andriantsoanirina V, Menard D, Tuseo L, *et al.* Résistance de *Plasmodium falciparum* aux antipaludiques : impact sur la pré-élimination du paludisme à Madagascar. *Med Trop* 2011 ; 71 : 298-304.
9. Andriantsoanirina V, Ratsimbao A, Bouchier C, *et al.* *Plasmodium falciparum* drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility. *Antimicrob Agents Chemother* 2009 ; 53 : 4588-97.
10. Andriantsoanirina V, Ratsimbao A, Bouchier C, *et al.* Chloroquine clinical failures in *P. falciparum* malaria are associated with mutant Pfmdr-1, not Pfcrt in Madagascar. *PLoS One* 2010 ; 5 : e13281.
11. Arie F, Duchemin JB, Robert V. Metapopulation concepts applied to *falciparum* malaria and their impacts on the emergence and spread of chloroquine resistance. *Infect Genet Evol* 2003 ; 2 : 185-92.
12. Arie F, Fandeur T, Durand R, *et al.* Invasion of Africa by a single pfcrt allele of South East Asian type. *Malar J* 2006 ; 5 : 34.
13. Arie F, Randrianarivelojosia M, Duchemin JB, *et al.* Mapping of a *Plasmodium falciparum* pfcrt K76T mutation: a useful strategy for controlling chloroquine resistance in Madagascar. *J Infect Dis* 2002 ; 185 : 710-2.
14. Arie F, Robert V. The puzzling links between malaria transmission and drug resistance. *Trends Parasitol.* 2003 ; 19 : 158-60; author reply 160-1.
15. Bacon DJ, Jambou R, Fandeur T, *et al.* World antimalarial resistance network (WARN) II: *in vitro* antimalarial drug susceptibility. *Malar J* 2007 ; 6 : 120.
16. Barnes KI, Lindegardh N, Ogundahunsi O, *et al.* World antimalarial resistance network (WARN) IV: clinical pharmacology. *Malar J* 2007 ; 6 : 122.
17. Berger F, Flamand C, Musset L, *et al.* Investigation of a sudden malaria outbreak in the isolated Amazonian village of Saul, French Guiana, January-April 2009. *Am J Trop Med Hyg* 2012 ; 86 : 591-7.
18. Biot C, Daher W, Chavain N, *et al.* Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. *J Med Chem* 2006 ; 49 : 2845-9.
19. Bob NS, Diop BM, Renaud F, *et al.* Parasite polymorphism and severe malaria in Dakar (Senegal): a West African urban area. *PLoS One* 2010 ; 5 : e9817.
20. Bogue H, Renaud F, Bouchiba H, *et al.* Genetic diversity and structure of African *Plasmodium falciparum* populations in urban and rural areas. *Am J Trop Med Hyg* 2006 ; 74 : 953-9.

21. Chim P, Lim P, Sem R, *et al.* The *in-vitro* antimalarial activity of ferrochloroquine, measured against Cambodian isolates of *Plasmodium falciparum*. *Ann Trop Med Parasitol* 2004 ; 98 : 419-24.
22. Cramer A, Marfurt J, Mugittu K, *et al.* Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. *J Clin Microbiol* 2007 ; 45 : 3685-91.
23. Daher W, Biot C, Fandeur T, *et al.* Assessment of *Plasmodium falciparum* resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure. *Malar J* 2006 ; 5 : 11.
24. Das D, Tripura R, Phyto AP, *et al.* Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant *falciparum* malaria. *Clin Infect Dis* 2012 ; 56 : e48-58.
25. Denis MB, Davis TM, Hewitt S, *et al.* Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated *falciparum* malaria. *Clin Infect Dis* 2002 ; 35 : 1469-76.
26. Denis MB, Tsuyuoka R, Lim P, *et al.* Efficacy of artemether-lumefantrine for the treatment of uncomplicated *falciparum* malaria in northwest Cambodia. *Trop Med Int Health* 2006 ; 11 : 1800-7.
27. Dolmazon V, Matsika-Claquin MD, Manirakiza A, *et al.* Genetic diversity and genotype multiplicity of *Plasmodium falciparum* infections in symptomatic individuals living in Bangui (CAR). *Acta Trop* 2008 ; 107 : 37-42.
28. Dondorp AM, Nosten F, Yi P, *et al.* Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* 2009 ; 361 : 455-67.
29. Duong S, Lim P, Fandeur T, *et al.* Importance of protection of antimalarial combination therapies. *Lancet* 2004 ; 364 : 1754-5.
30. Durand R, Arie F, Cojean S, *et al.* Analysis of circulating populations of *Plasmodium falciparum* in mild and severe malaria in two different epidemiological patterns in Madagascar. *Trop Med Int Health* 2008 ; 13 : 1392-9.
31. Ekala MT, Khim N, Legrand E, *et al.* Sequence analysis of *Plasmodium falciparum* cytochrome b in multiple geographic sites. *Malar J* 2007 ; 6 : 164.
32. Esterre P, Volney B, Meynard JB, Legrand E. Intérêt d'un observatoire régional de la chimiorésistance du paludisme, problème émergent de santé publique dans la région des Guyanes. *Bull Soc Pathol Exot* 2009 ; 102 : 179-84.
33. Farnert A, Arez AP, Babiker HA, *et al.* Genotyping of *Plasmodium falciparum* infections by PCR: a comparative multicentre study. *Trans R Soc Trop Med Hyg* 2001 ; 95 : 225-32.

34. Faye B, Offianan AT, Ndiaye JL, *et al.* Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) *versus* artemether-lumefantrine (Coartem) against uncomplicated *Plasmodium falciparum* malaria: multisite trial in Senegal and Ivory Coast. *Trop Med Int Health* 2010 ; 15 : 608-13.
35. Gaillard T, Fall B, Tall A, *et al.* Absence of association between *ex vivo* susceptibility to doxycycline and pftetQ and pfmdt copy numbers in *Plasmodium falciparum* isolates from Dakar, Senegal. *Clin Microbiol Infect* 2012 ; 18 : E238-40.
36. Hodel EM, Genton B, Zanolari B, *et al.* Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure. *J Infect Dis* 2010 ; 202 : 1088-94.
37. Hodel EM, Ley SD, Qi W, *et al.* A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs. *Malar J* 2009 ; 8 : 285.
38. Ibrahim ML, Gay-Andrieu F, Adehossi E, *et al.* Field-based evidence for the linkage of pfcrt and pfdhfr drug-resistant malaria genotypes and clinical profiles of severe malaria in Niger. *Microbes Infect* 2007 ; 9 : 599-604.
39. Ibrahim ML, Khim N, Adam HH, *et al.* Polymorphism of PfATPase in Niger: detection of three new point mutations. *Malar J* 2009 ; 8 : 28.
40. Ibrahim ML, Steenkeste N, Khim N, *et al.* Field-based evidence of fast and global increase of *Plasmodium falciparum* drug-resistance by DNA-microarrays and PCR/RFLP in Niger. *Malar J* 2009 ; 8 : 32.
41. Incardona S, Vong S, Chiv L, *et al.* Large-scale malaria survey in Cambodia: novel insights on species distribution and risk factors. *Malar J* 2007 ; 6 : 37.
42. Jambou R, Le Bras J, Randrianariveolosia M. Pitfalls in new artemisinin-containing antimalarial drug development. *Trends Parasitol* 2010 ; 27 : 82-90.
43. Jambou R, Legrand E, Niang M, *et al.* Resistance of *Plasmodium falciparum* field isolates to *in-vitro* artemether and point mutations of the SERCA-type PfATPase6. *Lancet* 2005 ; 366 : 1960-3.
44. Jambou R, Martinelli A, Pinto J, *et al.* Geographic structuring of the *Plasmodium falciparum* sarco(endo)plasmic reticulum Ca<sup>2+</sup> ATPase (PfSERCA) gene diversity. *PLoS One* 2010 ; 5 : e9424.
45. Jansen FH, Lesaffre E, Penali LK, *et al.* Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis. *Am J Trop Med Hyg* 2007 ; 77 : 1005-9.

46. Juliano JJ, Arie F, Sem R, *et al.* Misclassification of drug failure in *Plasmodium falciparum* clinical trials in southeast Asia. *J Infect Dis* 2009 ; 200 : 624-8.
47. Juliano JJ, Randrianariveolosia M, Ramarosandratana B, *et al.* Nonradioactive heteroduplex tracking assay for the detection of minority-variant chloroquine-resistant *Plasmodium falciparum* in Madagascar. *Malar J* 2009 ; 8 : 47.
48. Khim N, Bouchier C, Ekala MT, *et al.* Countrywide survey shows very high prevalence of *Plasmodium falciparum* multilocus resistance genotypes in Cambodia. *Antimicrob Agents Chemother* 2005 ; 49 : 3147-52.
49. Khim N, Kim S, Bouchier C, *et al.* Reduced impact of pyrimethamine drug pressure on *Plasmodium malariae* dihydrofolate reductase gene. *Antimicrob Agents Chemother* 2012 ; 56 : 863-8.
50. Leang R, Barrette A, Bouth DM, *et al.* Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated *Plasmodium falciparum* and *Plasmodium vivax* in Cambodia, 2008 to 2010. *Antimicrob Agents Chemother* 2012 ; 57 : 818-26.
51. Legrand E, Demar M, Volney B, *et al.* First case of emergence of atovaquone resistance in *Plasmodium falciparum* during second-line atovaquone-proguanil treatment in South America. *Antimicrob Agents Chemother* 2007 ; 51 : 2280-1.
52. Legrand E, Volney B, Lavergne A, *et al.* Molecular analysis of two local *falciparum* malaria outbreaks on the French Guiana coast confirms the msp1 B-K1/varD genotype association with severe malaria. *Malar J* 2005 ; 4 : 26.
53. Legrand E, Volney B, Meynard JB, *et al.* Resistance to dihydroartemisinin. *Emerg Infect Dis* 2007 ; 13 : 808-9; author reply 809.
54. Legrand E, Volney B, Meynard JB, *et al.* *In vitro* monitoring of *Plasmodium falciparum* drug resistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. *Antimicrob Agents Chemother* 2008 ; 52 : 288-98.
55. Legrand E, Yrinesi J, Ekala MT, *et al.* Discordant temporal evolution of Pfert and Pfmdr1 genotypes and *Plasmodium falciparum in vitro* drug susceptibility to 4-aminoquinolines after drug policy change in French Guiana. *Antimicrob Agents Chemother* 2012 ; 56 : 1382-9.
56. Lim P, Alker AP, Khim N, *et al.* Pfmdr1 copy number and artemisinin derivatives combination therapy failure in *falciparum* malaria in Cambodia. *Malar J* 2009 ; 8 : 11.
57. Lim P, Chim P, Sem R, *et al.* *In vitro* monitoring of *Plasmodium falciparum* susceptibility to artesunate, mefloquine, quinine and chloroquine in Cambodia: 2001-2002. *Acta Trop* 2005 ; 93 : 31-40.

58. Lim P, Chy S, Arieu F, *et al.* pfcrt polymorphism and chloroquine resistance in *Plasmodium falciparum* strains isolated in Cambodia. *Antimicrob Agents Chemother* 2003 ; 47 : 87-94.
59. Lim P, Wongsrichanalai C, Chim P, *et al.* Decreased *in vitro* susceptibility of *Plasmodium falciparum* isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. *Antimicrob Agents Chemother* 2010 ; 54 : 2135-42.
60. Maiga-Ascofare O, Le Bras J, Mazmouz R, *et al.* Adaptive differentiation of *Plasmodium falciparum* populations inferred from single-nucleotide polymorphisms (SNPs) conferring drug resistance and from neutral SNPs. *J Infect Dis* 2010 ; 202 : 1095-103.
61. Matsika-Claquin MD, Menard D, Fontanet AL, *et al.* Efficacy of chloroquine-proguanil malaria prophylaxis in a non-immune population in Bangui, Central African Republic: a case-control study. *Trans R Soc Trop Med Hyg* 2006 ; 100 : 381-6.
62. Menard D, Andrianina NN, Ramiandrasoa Z, *et al.* Randomized clinical trial of artemisinin *versus* non-artemisinin combination therapy for uncomplicated *falciparum* malaria in Madagascar. *Malar J* 2007 ; 6 : 65.
63. Menard D, Andriantsoanirina V, Jahevitra M, *et al.* Dihydrofolate reductase I164L mutation in *Plasmodium falciparum*, Madagascar. *Emerg Infect Dis* 2008 ; 14 : 1166-7.
64. Menard D, Djalle D, Manirakiza A, *et al.* Drug-resistant malaria in Bangui, Central African Republic: an *in vitro* assessment. *Am J Trop Med Hyg* 2005 ; 73 : 239-43.
65. Menard D, Djalle D, Yapou F, *et al.* Frequency distribution of antimalarial drug-resistant alleles among isolates of *Plasmodium falciparum* in Bangui, Central African Republic. *Am J Trop Med Hyg* 2006 ; 74 : 205-10.
66. Menard D, Madji N, Manirakiza A, *et al.* Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, chloroquine-sulfadoxine-pyrimethamine combination, and amodiaquine-sulfadoxine-pyrimethamine combination in Central African children with noncomplicated malaria. *Am J Trop Med Hyg* 2005 ; 72 : 581-5.
67. Menard D, Matsika-Claquin MD, Djalle D, *et al.* Association of failures of seven-day courses of artesunate in a non-immune population in Bangui, Central African Republic with decreased sensitivity of *Plasmodium falciparum*. *Am J Trop Med Hyg* 2005 ; 73 : 616-21.
68. Menard D, Randrianarivo-Solofoniaina AE, Ahmed BS, *et al.* Drug-resistant malaria parasites introduced into Madagascar from Comoros Islands. *Emerg Infect Dis* 2007 ; 13 : 1759-62.

69. Menard D, Ratsimbaoa A, Randrianariveolosia M, *et al.* Assessment of the efficacy of antimalarial drugs recommended by the National Malaria Control Programme in Madagascar: up-dated baseline data from randomized and multi-site clinical trials. *Malar J* 2008 ; 7 : 55.
70. Menard D, Yapou F, Manirakiza A. Polymorphisms in *pfprt*, *pfmdr1*, *dhfr* genes and *in vitro* responses to antimalarials in *Plasmodium falciparum* isolates from Bangui, Central African Republic. *Am J Trop Med Hyg* 2006 ; 75 : 381-7.
71. Mercereau-Puijalon O, Fandeur T. Antimalarial activity of artemisinins: identification of a novel target? *Lancet* 2003 ; 362 : 2035-6.
72. Ndiaye JL, Randrianariveolosia M, Sagara I, *et al.* Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated *Plasmodium falciparum* malaria. *Malar J* 2009 ; 8 : 125.
73. Niang M, Marrama L, Ekala MT, *et al.* Accumulation of CVIET *Pfprt* allele of *Plasmodium falciparum* in placenta of pregnant women living in an urban area of Dakar, Senegal. *J Antimicrob Chemother* 2008 ; 62 : 921-8.
74. Noranate N, Durand R, Tall A, *et al.* Rapid dissemination of *Plasmodium falciparum* drug resistance despite strictly controlled antimalarial use. *PLoS One* 2007 ; 2 : e139.
75. Offianan AT, Penali LK, Coulibaly M, *et al.* Comparative efficacy of uncontrolled and controlled intermittent preventive treatment during pregnancy (IPTp) with combined use of LLTNs in high resistance area to sulfadoxine-pyrimethamine in Côte d'Ivoire. *Infect Drug Resist* 2012 ; 5 : 53-63.
76. Pelleau S, Bertaux L, Briolant S, *et al.* Differential association of *Plasmodium falciparum* Na<sup>+</sup>/H<sup>+</sup> exchanger polymorphism and quinine responses in field- and culture-adapted isolates of *Plasmodium falciparum*. *Antimicrob Agents Chemother* 2011 ; 55 : 5834-41.
77. Penali L, Mulholland DA, Tano KD, *et al.* Low antiplasmodial activity of alkaloids and amides from the stem bark of *Zanthoxylum rubescens* (Rutaceae). *Parasite* 2007 ; 14 : 161-4.
78. Penali LK, Jansen FH. Single-day, three-dose treatment with fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine to cure *Plasmodium falciparum* malaria. *Int J Infect Dis* 2008 ; 12 : 430-7.
79. Pradines B, Mamfoumbi MM, Tall A, *et al.* *In vitro* activity of tafenoquine against the asexual blood stages of *Plasmodium falciparum* isolates from Gabon, Senegal, and Djibouti. *Antimicrob Agents Chemother* 2006 ; 50 : 3225-6.

80. Pradines B, Spiegel A, Rogier C, *et al.* Antibiotics for prophylaxis of *Plasmodium falciparum* infections: *in vitro* activity of doxycycline against Senegalese isolates. *Am J Trop Med Hyg* 2000 ; 62 : 82-5.
81. Pradines B, Tall A, Ramiandrasoa F, *et al.* *In vitro* activity of iron-binding compounds against Senegalese isolates of *Plasmodium falciparum*. *J Antimicrob Chemother* 2006 ; 57 : 1093-9.
82. Pradines B, Tall A, Rogier C, *et al.* *In vitro* activities of ferrochloroquine against 55 Senegalese isolates of *Plasmodium falciparum* in comparison with those of standard antimalarial drugs. *Trop Med Int Health* 2002 ; 7 : 265-70.
83. Rabarijaona LP, Arieu F, Matra R, *et al.* Low autochthonous urban malaria in Antananarivo (Madagascar). *Malar J* 2006 ; 5 : 27.
84. Raharimalala AL, Randrianariveolosia M, Randriamanantena A, *et al.* Sensibilité de *Plasmodium falciparum* dans l'île de Sainte Marie, côte Est de Madagascar : études *in vivo* et *in vitro*. *Arch Inst Pasteur Madagascar* 2000 ; 66 : 26-31.
85. Randrianariveolosia M, Fidock DA, Belmonte O, *et al.* First evidence of pfcrt mutant *Plasmodium falciparum* in Madagascar. *Trans R Soc Trop Med Hyg* 2006 ; 100 : 826-30.
86. Randrianariveolosia M, Harisoa JL, Rabarijaona LP, *et al.* *In vitro* sensitivity of *Plasmodium falciparum* to amodiaquine compared with other major antimalarials in Madagascar. *Parassitologia* 2002 ; 44 : 141-7.
87. Randrianariveolosia M, Raharimalala L, Randriamanantena A, Jambou R. Chimiorésistance de *Plasmodium falciparum* dans les régions côtières malgaches. *Med Trop* 2000 ; 60 : 243-9.
88. Randrianariveolosia M, Raharimalala LA, Randrianasolo L, *et al.* Madagascan isolates of *Plasmodium falciparum* showing low sensitivity to artemether *in vitro*. *Ann Trop Med Parasitol* 2001 ; 95 : 237-43.
89. Randrianariveolosia M, Raheinjafy RH, Migliani R, *et al.* *Plasmodium falciparum* resistant to chloroquine and to pyrimethamine in Comoros. *Parasite* 2004 ; 11 : 419-23.
90. Randrianariveolosia M, Rakotonjanabelo LA, Mauclere P, *et al.* Réseau d'Etude de la Résistance (RER) pour pérenniser la surveillance de la sensibilité de *Plasmodium falciparum* aux antipaludiques à Madagascar. *Arch Inst Pasteur Madagascar* 2002 ; 68 : 73-8.
91. Randrianariveolosia M, Randrianasolo L, Randremanana RV, *et al.* Susceptibility of *Plasmodium falciparum* to the drugs used to treat severe malaria (quinine) and to prevent



- malaria (mefloquine, cycloguanil) in Comoros Union and Madagascar. *S Afr Med J* 2004 ; 94 : 47-51.
92. Randrianariveლოსია M, Ratsimbasoa A, Randrianasolo L, *et al.* *In-vitro* sensitivity of *Plasmodium falciparum* to chloroquine, halofantrine, mefloquine and quinine in Madagascar. *East Afr Med J* 2002 ; 79 : 237-41.
93. Randrianariveლოსია M, Raveloson A, Randriamanantena A, *et al.* Lessons learnt from the six decades of chloroquine use (1945–2005) to control malaria in Madagascar. *Trans R Soc Trop Med Hyg* 2009 ; 103 : 3-10.
94. Randrianariveლოსია M, Sahondra-Harisoa JL, Raharimalala LA, *et al.* Évaluation *in vitro* de la sensibilité de *Plasmodium falciparum* à la chloroquine dans la région de l’Océan Indien dans le cadre du réseau d’étude de la résistance (RER). *Sante* 2003 ; 13 : 95-100.
95. Randrianasolo L, Randriamanantena A, Ranarivelo L, *et al.* Monitoring susceptibility to sulfadoxine-pyrimethamine among cases of uncomplicated, *Plasmodium falciparum* malaria in Saharevo, Madagascar. *Ann Trop Med Parasitol* 2004 ; 98 : 551-4.
96. Randrianasolo L, Randriamanantena A, Ratsimbasoa A, *et al.* Surveillance de l’efficacité de sulfadoxine-pyriméthamine (Fansidar®, Paludar®) pour le traitement de l’accès palustre à Madagascar : proposition d’un protocole simplifié. *Arch Inst Pasteur Madagascar* 2003 ; 69 : 52-6.
97. Rason MA, Arieய F, Rafidimanantsoa L, *et al.* Monitoring the drug-sensitivity of *Plasmodium falciparum* in coastal towns in Madagascar by use of *in vitro* chemosensitivity and mutation detection tests. *Parasite* 2002 ; 9 : 247-53.
98. Ratsimbasoa A, Randrianariveლოსია M, Millet P, *et al.* Use of pre-packaged chloroquine for the home management of presumed malaria in Malagasy children. *Malar J* 2006 ; 5 : 79.
99. Ratsimbasoa A, Ravony H, Vonimpaisomihanta JA, *et al.* Compliance, safety, and effectiveness of fixed-dose artesunate-amodiaquine for presumptive treatment of non-severe malaria in the context of home management of malaria in Madagascar. *Am J Trop Med Hyg* 2012 ; 86 : 203-10.
100. Razakandrainibe R, Thonier V, Ratsimbasoa A, *et al.* Epidemiological situation of malaria in Madagascar: baseline data for monitoring the impact of malaria control programmes using serological markers. *Acta Trop* 2009 ; 111 : 160-7.

101. Robert V, Le Goff G, Andrianaivolambo L, *et al.* Moderate transmission but high prevalence of malaria in Madagascar. *Int J Parasitol* 2006 ; 36 : 1273-81.
102. Rogers WO, Sem R, Tero T, *et al.* Failure of artesunate-mefloquine combination therapy for uncomplicated *Plasmodium falciparum* malaria in southern Cambodia. *Malar J* 2009 ; 8 : 10.
103. Rogier C, Pradines B, Bogreau H, *et al.* Malaria epidemic and drug resistance, Djibouti. *Emerg Infect Dis* 2005 ; 11 : 317-21.
104. Rueangweerayut R, Phyto AP, Uthaisin C, *et al.* Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. *N Engl J Med* 2012 ; 366 : 1298-309.
105. Shah NK, Alker AP, Sem R, *et al.* Molecular surveillance for multidrug-resistant *Plasmodium falciparum*, Cambodia. *Emerg Infect Dis* 2008 ; 14 : 1637-40.
106. Socheat D, Denis MB, Fandeur T, *et al.* Mekong malaria. II. Update of malaria, multi-drug resistance and economic development in the Mekong region of Southeast Asia. *Southeast Asian J Trop Med Public Health* 2003 ; 34 Suppl 4 : 1-102.
107. Sokhna CS, Rogier C, Dieye A, Trape JF. Host factors affecting the delay of reappearance of *Plasmodium falciparum* after radical treatment among a semi-immune population exposed to intense perennial transmission. *Am J Trop Med Hyg* 2000 ; 62 : 266-70.
108. Steenkeste N, Dillies MA, Khim N, *et al.* FlexiChip package: an universal microarray with a dedicated analysis software for high-throughput SNPs detection linked to anti-malarial drug resistance. *Malar J* 2009 ; 8 : 229.
109. Steenkeste N, Rogers WO, Okell L, *et al.* Sub-microscopic malaria cases and mixed malaria infection in a remote area of high malaria endemicity in Rattanakiri province, Cambodia: implication for malaria elimination. *Malar J* 2010 ; 9 : 108.
110. Tall A, Rabarijaona LP, Robert V, *et al.* Efficacy of artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, and chloroquine plus sulfadoxine-pyrimethamine in patients with uncomplicated *Plasmodium falciparum* in the Comoros Union. *Acta Trop* 2007 ; 102 : 176-81.
111. Tall A, Raharimalala LA, Lepere JF, *et al.* Efficacy of artemether-lumefantrine treatment in patients with acute uncomplicated *falciparum* malaria in Mayotte, a French collectivity of the Comoros Archipelago. *Parasite* 2004 ; 11 : 325-8.
112. Talman AM, Duval L, Legrand E, *et al.* Evaluation of the intra- and inter-specific genetic variability of *Plasmodium* lactate dehydrogenase. *Malar J* 2007 ; 6 : 140.

113. Talman AM, Paul RE, Sokhna CS, *et al.* Influence of chemotherapy on the *Plasmodium* gametocyte sex ratio of mice and humans. *Am J Trop Med Hyg* 2004 ; 71 : 739-44.
114. Tanabe K, Zakeri S, Palacpac NM, *et al.* Spontaneous mutations in the *Plasmodium falciparum* sarcoplasmic/ endoplasmic reticulum Ca<sup>2+</sup>-ATPase (PfATP6) gene among geographically widespread parasite populations unexposed to artemisinin-based combination therapies. *Antimicrob Agents Chemother* 2011 ; 55 : 94-100.
115. Toure OA, Kouame MG, Didier YJ, *et al.* Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated *Plasmodium falciparum* in Anonkoua koute, Côte d'Ivoire. *Trop Med Int Health* 2011 ; 16 : 290-7.
116. Toure OA, Penali LK, Yapi JD, *et al.* A comparative, randomized clinical trial of artemisinin/naphthoquine twice daily one day *versus* artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire. *Malar J* 2009 ; 8 : 148.
117. Valderramos SG, Valderramos JC, Musset L, *et al.* Identification of a mutant PfCRT-mediated chloroquine tolerance phenotype in *Plasmodium falciparum*. *PLoS Pathog* 2010 ; 6 : e1000887.
118. Vinayak S, Alam MT, Mixson-Hayden T, *et al.* Origin and evolution of sulfadoxine resistant *Plasmodium falciparum*. *PLoS Pathog* 2010 ; 6 : e1000830.
119. Vinayak S, Alam MT, Sem R, *et al.* Multiple genetic backgrounds of the amplified *Plasmodium falciparum* multidrug resistance (pfmdr1) gene and selective sweep of 184F mutation in Cambodia. *J Infect Dis* 2010 ; 201 : 1551-60.
120. Witkowski B, Khim N, Chim P, *et al.* Reduced artemisinin susceptibility of *Plasmodium falciparum* ring stages in western Cambodia. *Antimicrob Agents Chemother* 2012 ; 57 : 914-23.
121. Yalcindag E, Elguero E, Arnathau C, *et al.* Multiple independent introductions of *Plasmodium falciparum* in South America. *Proc Natl Acad Sci USA* 2012 ; 109 : 511-6.
122. Zwang J, Olliaro P, Barennes H, *et al.* Efficacy of artesunate-amodiaquine for treating uncomplicated *falciparum* malaria in sub-Saharan Africa: a multi-centre analysis. *Malar J* 2009 ; 8 : 203.